Exhaustion News and Research

RSS

New study pinpoints key source of T cell "exhaustion"

Custom-made to attack cancer cells, CAR T-cell therapies have opened a new era in the treatment of human cancers, particularly, in hematologic malignancies.

21 Mar 2023

Potential approach to improve solid tumor T cell therapy

Researchers at the Perelman School of Medicine at the University of Pennsylvania have been working on a preclinical study that focuses on a new strategy that uses a “one-two punch” to assist T cells in attacking solid tumors.

17 Mar 2023

Age-related sarcopenia prevented by AAV1.NT-3 gene therapy

A new research paper was published on the cover of Aging (listed by MEDLINE/PubMed as "Aging (Albany NY)" and "Aging-US" by Web of Science) Volume 15, Issue 5, entitled, "AAV1.NT-3 gene therapy prevents age-related sarcopenia."

16 Mar 2023

Study sheds light on why lung tumors do not respond well to immunotherapy

Immunotherapy -; drug treatment that stimulates the immune system to attack tumors -; works well against some types of cancer, but it has shown mixed success against lung cancer.

6 Feb 2023

Inexpensive recombinant protein production induced by urea

A common chemical present in the urine can be utilized to initiate large-scale production of proteins needed by biotech companies, like hormones and antibodies.

28 Oct 2022

Scientists demonstrate a new function of an enzyme that connects to age-related diseases

Aging and age-related diseases present a complex challenge to biomedical researchers.

20 Jul 2022

Researchers conduct a comprehensive survey of the aging epigenome across the chromatin hierarchy

Highly structured chromatin encodes the program of life with only one set of genes in the core of every cell. Since various genes are stimulated at different periods of life while staying silent elsewhere, this is feasible. Some genes from a former life stage are hidden deep within the nuclear perimeter, while others manage to break out.

1 Jun 2022

National DNA Day 2022: an interview with Professor Matthew Cobb

To celebrate National DNA Day 2022, we spoke to science communicator Professor Matthew Cobb.

From The University of Manchester 25 Apr 2022

Study reveals key characteristics of immune cells in ovarian cancer

Ovarian cancer is a difficult to diagnose malignancy that is often caught at a more advanced stage. Treatments for this cancer have changed little over the past few decades, with surgery and chemotherapy being the most common therapeutic approaches.

15 Apr 2022

Researchers create RNA molecules to address human pancreatic beta cells

Researchers at the University of Miami Miller School of Medicine have created RNA molecules that bind to human pancreatic beta cells, which generate insulin and are destroyed in type 1 and type 2 diabetes patients.

11 Apr 2022

Checkpoint immunotherapy acts as an interface between killer T cells and dendritic cells

Chronic viral infections and cancers can damage the immune system permanently, diminishing the ability of immune killer T cells to destroy tumor cells or virus-infected cells—a condition known as “immune exhaustion.”

5 Apr 2022

HIF-1alpha inhibitor preserves the activity of insulin-producing beta cells in diabetic mice

High blood glucose is responsible for several complications in type 1 and type 2 diabetes. Researchers at Karolinska Institutet in Sweden have identified a new antidiabetic substance that preserves the activity of insulin-producing beta cells and prevents high blood glucose in mice.

31 Mar 2022

CAR-T cell treatment via implantable biotechnology more effective in combating cancer

Researchers from North Carolina State University and the University of North Carolina at Chapel Hill have developed an implantable biotechnology that produces and releases CAR-T cells for attacking cancerous tumors.

25 Mar 2022

Single-cell spatial analysis may provide information about neoadjuvant therapy for triple-negative breast cancer

A next-generation technology that allows the study of protein expression at the single-cell level and the location of the cells within the tumor microenvironment (TME) was feasible and provided information on the benefit of adding the immune checkpoint inhibitor atezolizumab (Tecentriq) to chemotherapy as neoadjuvant treatment for patients with early high-risk and locally advanced triple negative breast cancer (TNBC), according to results presented at the San Antonio Breast Cancer Symposium, held December 7-10, 2021.

8 Dec 2021

Pacific Ocean rockfish genomes offer new insights into the genetic determinants of aging

Genomes assembled from Pacific Ocean rockfishes – some species of which are among the longest-living vertebrates known – reveal new insights into the genetic determinants of aging.

12 Nov 2021

Study reveals what causes T cells to be non-responsive to immunotherapy

Non-small cell lung cancer is the most common type of lung cancer in humans. Some patients with NSCLC receive a therapy called immune checkpoint blockade (ICB) that helps kill cancer cells by reinvigorating a subset of immune cells called T cells, which are "exhausted" and have stopped working.

1 Nov 2021

Vaccinating against certain cancer proteins can boost overall immune response and shrink tumors

Over the past decade, scientists have been exploring vaccination as a way to help fight cancer. These experimental cancer vaccines are designed to stimulate the body's own immune system to destroy a tumor, by injecting fragments of cancer proteins found on the tumor.

17 Sep 2021